2023 30 November 2023 – Results of Annual General Meeting30 November 2023 – Chairman’s address and CEO update31 October 2023 – Quarterly Activities/Appendix 4C Cash Flow Report27 October 2023 – Letter to Shareholders – AGM 202327 October 2023 – Notice of Meeting 20235 October 2023 – Date of AGM29 September 2023 – Appendix 4G and Corporate Governance Statement29 September 2023 – Annual Report 202328 September 2023 – Cambium Bio – Shareholder Update presentation31 August 2023 – Appendix 4E – Preliminary final report-unaudited31 July 2023 – Quarterly Cashflow Report & Business Update Jun 20236 July 2023 – RGS Response to ASX Price query1 May 2023 – Change in substantial holding28 April 2023 – Quarterly Cashflow Report & Business Update Mar 202328 April 2023 – Regeneus Merger with Cambium28 February 2023 – Half Yearly Report and Accounts28 February 2023 – Regeneus agrees to settle $2m loan31 January 2023 – Quarterly Cashflow Report & Business Update Dec 202231 January 2023 – Notice of Termination of Kyocera Licence30 January 2023 – Regeneus Trading Halt 2022 20 December 2022 – Regeneus receives $1.1 million R&D Tax Incentive Refund29 November 2022 – Result of AGM 202229 November 2022 – Change of Auditor29 November 2022 – AGM 2022 Chairman’s Address and CEO presentation28 October 2022 – Quarterly Cashflow Report & Business Update Sep 202228 October 2022 – Notice of Meeting28 October 2022 – Letter to Shareholder – AGM30 September 2022 – Date of AGM30 August 2022 – RGS Annual report 202230 August 2022 – Appendix 4G and Corporate Governance21 July 2022 – Quarterly Cashflow Report & Business Update June 202217 June 2022 – Change of Director’s Interest Notice – Graham Vesey10 June 2022 – Regeneus CEO cements support29 April 2022 – Quarterly Activities/Appendix 4C Cash Flow Report2 March 2022 – Director Appointment/Resignation25 February 2022 – Half yearly report and accounts25 February 2022 – Grant of ASX Waiver4 February 2022 – Lapse of Unlisted Share Options28 January 2022 – Quarterly Activities/Appendix 4C Cash Flow Report28 January 2022 – Appointment of Board Advisor 2021 22 December 2021 – Regeneus Market Update18 November 2021 – Results of Annual General Meeting18 November 2021 – Chairman’s Address to Shareholders17 November 2021 – Supplementary Announcement – Appendix 4C5 November 2021 – Investor Update Webcast – November 20215 November 2021 – Amendment to Institutional Placement29 October 2021 – Quarterly Activities/Appendix 4C Cash Flow Report28 October 2021 – Regeneus Corporate Presentation (October 2021)26 October 2021 – Revised Securities Trading Policy26 October 2021 – Appendix 4G and Corporate Governance Statement26 October 2021 – Annual Report 202125 October 2021 – Regeneus Company Update Investor Webcast Presentation15 October 2021 – Virtual Annual General Meeting Online Guide15 October 2021 – Notice of Annual General Meeting / Proxy / Question Form14 October 2021 – Application for quotation of securities – RGS14 October 2021 – Cleansing Statement20 September 2021 – Revised Date of AGM31 August 2021 – Appendix 4E – Preliminary final report-unaudited19 August 2021 – Date of AGM9 August 2021 – Lapse of Unlisted Share Options9 August 2021 – Notification of cessation of securities – RGS9 August 2021 – Lapse of Unlisted Share Options – correction29 July 2021 – Quarterly Activities Appendix 4C Cash Flow Report28 July 2021 – R&D Collaboration with Kolling Institute30 June 2021 – Change of Company Secretary12 May 2021 – Cleansing Statement12 May 2021 – Appendix 2A7 May 2021 – Proposed issue of Securities – RGS7 May 2021 – Regeneus Announces Institutional Placement5 May 2021 – Grant of Options to CEO and Appendix 3G30 April 2021 – Appendix 4C – Quarterly29 April 2021 – Regeneus partners with Defence to treat combat casualties16 March 2021 – Regeneus to be granted key Progenza patent in Europe3 March 2021 – Regeneus Company Update Investor Webcast Presentation1 March 2021 – Appendix 3Z Final Director’s Interest Notice Dr Alan Dunton26 February 2021 – Half-Year Results and Business Update26 February 2021 – Appendix 4D and Half-Year Report25 February 2021 – Regeneus Company Update Investor Webcast Notification25 February 2021 – Resignation of Non Executive Director Dr Alan Dunton9 February 2021 – Regeneus to be granted new patent to target pain in Japan5 February 2021 – Response to ASX Appendix 4C Query5 February 2021 – Clarification on Quarterly Activity Report and Appendix 4C29 January 2021 – Appendix 4C – Quarterly Report 2020 19 November 2020 – Lapse of Unlisted Share Options19 November 2020 – Appendix 3Y – Leo Lee19 November 2020 – Appendix 3Y – Alan Dunton19 November 2020 – Appendix 3Y – John Chiplin19 November 2020 – Appendix 3Y – Graham Vesey11 November 2020 – Clarification on Quarterly Activity Report and Appendix 4C2 November 2020 – Material Terms of Contract for Chief Executive Officer2 November 2020 – CEO Appointment and Resignation30 October 2020 – Annual Report Additional Information30 October 2020 – Appendix 4C – Quarterly29 October 2020 – Regeneus receives $5.6M milestone payment from Kyocera14 October 2020 – Results of Annual General Meeting14 October 2020 – AGM Chairman’s Address and CEO Presentation7 October 2020 – Regeneus to be granted new Sygenus patent in Canada1 October 2020 – Australian Biomarker Patent Allowed29 September 2020 – Regeneus receives $676k in R&D Tax Incentives11 September 2020 – Notice of initial substantial holder – AGC Inc.11 September 2020 – Virtual Annual General Meeting Online Guide11 September 2020 – Notice of Annual General Meeting / Proxy / Question Form10 September 2020 – Issue of AGC shares complete10 September 2020 – Appendix 2A10 September 2020 – Cleansing Notice8 September 2020 – Notice of initial substantial holder – Kirman 2 Pty Ltd3 September 2020 – Appendix 3G3 September 2020 – Appendix 3Y – Leo Lee3 September 2020 – CEO bonus payment28 August 2020 – Regeneus receives milestone payment from Kyocera28 August 2020 – Appendix 4G and Corporate Governance Statement28 August 2020 – Appendix 4E and Annual Report25 August 2020 – Regeneus to present at FNN Virtual Investor Event19 August 2020 – Regeneus to be granted new Sygenus patent in US11 August 2020 – Regeneus and Kyocera sign Progenza OA deal7 August 2020 – Trading Halt5 August 2020 – Date of AGM31 July 2020 – Appendix 4C – Quarterly28 July 2020 – Progenza OA licence with Kyocera enters final negotiation phase6 July 2020 – Appendix 3G4 June 2020 – Appendix 3Z – Final Director’s Interest Notice4 June 2020 – Director Resignation18 May 2020 – Kyocera completes Progenza Due Diligence5 May 2020 – Appendix 4C – Quarterly (Updated)29 April 2020 – Appendix 4C – Quarterly1 April 2020 – Appendix 3G23 March 2020 – Regeneus to be granted new key Progenza patent in U.S.20 March 2020 – Regeneus receives A$1.6M milestone payment from Kyocera2 March 2020 – Regeneus signs MOU agreement with Kyocera on exclusive negotiation rights for Progenza in Japan28 February 2020 – Half-Year Results & Business Update28 February 2020 – Appendix 4D and Half-Year Report28 February 2020 – Directors provide $4M loan to support commercial license discussions6 February 2020 – ASX Response Letter & 3Ys6 February 2020 – Appendix 3G31 January 2020 – Appendix 4C – Quarterly20 January 2020 – Appendix 3G 2019 20 December 2019 – Proposed issue of Securities – RGS20 December 2019 – AGC Agreement termination paves way for commercial partner18 December 2019 – RGS receives Innovation Grant21 November 2019 – Results of the Annual General Meeting21 November 2019 – CEO Presentation to 2019 Annual General Meeting21 November 2019 – Chairman’s Address to Shareholders20 November 2019 – Cleansing Statement20 November 2019 – Appendix 3B19 November 2019 – Japanese Biotech Fund takes up all Rights Issue Shortfall31 October 2019 – Response to ASX Appendix 4C Query31 October 2019 – Appendix 4C – Quarterly30 October 2019 – Appendix 4G and Corporate Governance Statement30 October 2019 – Annual Report 201919 October 2019 – Change of Registered Office and Principal Place of Business18 October 2019 – Notice of Annual General Meeting / Proxy Form15 October 2019 – Regeneus receives A$1.5 million in R&D Tax Incentives26 September 2019 – Financial Report – Year Ended 30 June 201911 September 2019 – Notice of initial substantial holder – Leo Lee11 September 2019 – Change of interests of substantial holder – Graham Vesey10 September 2019 – Date of AGM3 September 2019 – Appendix 3Y – Barry Sechos3 September 2019 – Appendix 3Y – Leo Lee3 September 2019 – Appendix 3Y – Glen Richards3 September 2019 – Appendix 3B30 August 2019 – Rights Issue Shortfall Notice30 August 2019 – Clarification to announcement30 August 2019 – Appendix 4E13 August 2019 – Confirmation of Despatch of Offer Booklet13 August 2019 – Restructuring results in 50% reduction in operating costs7 August 2019 – Updated Investor Presentation7 August 2019 – Placement Appendix 3B and Cleansing Statement2 August 2019 – Letter to Shareholders – Non Renounceable Rights Issue1 August 2019 – Investor Presentation1 August 2019 – Letter to Option holders1 August 2019 – Offer Booklet1 August 2019 – Cleansing Notice1 August 2019 – Successful Private Placement1 August 2019 – Appendix 3B31 July 2019 – Appendix 4C – Quarterly30 July 2019 – Trading Halt23 July 2019 – Positive results for Progenza in treating neuropathic pain22 July 2019 – New Strategy To Deliver Therapies For Global Pain Market2 May 2019 – Appendix 3Z – Final Director Interest Notice2 May 2019 – Appendix 3X – Initial Director Interest Notice29 April 2019 – Regeneus Appoints International Directors for Global Growth11 April 2019 – Appendix 4C – Quarterly28 February 2019 – Appendix 4D and Half-Year Report28 February 2019 – Directors Provide $2.5M Loan to Extend Funding Runway2 February 2019 – Response to ASX Appendix 4C Query Letter2 February 2019 – Material Terms of Contract for Chief Executive Officer30 January 2019 – Appendix 4C – Quarterly23 January 2019 – New CEO Appointed to Accelerate Global Growth See the full archive Subscribe to our investor newsletterSubscribe to Regeneus' investor newsletter for the latest information and updates Your first Name Your email Subscribe
